Leukemia Research
Volume 29, Issue 2 , Pages 185-196 , February 2005

In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8

  • Anita Ryningen

      Affiliations

    • Division for Hematology, Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway
    • Corresponding Author InformationCorresponding author. Tel.: +47 55 97 50 00; fax: +47 55 97 29 50.
    • ,
  • Line Wergeland

      Affiliations

    • The University of Bergen, N-5021 Bergen, Norway
    • ,
  • Nils Glenjen

      Affiliations

    • Division for Hematology, Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway
    • ,
  • Bjørn Tore Gjertsen

      Affiliations

    • Division for Hematology, Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway
    • ,
  • Øystein Bruserud

      Affiliations

    • Division for Hematology, Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway

Received 16 February 2004 ,Accepted 14 June 2004.

References 

  1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051–1062
  2. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukemia derived from the MRC AML 10 trial. Br. J. Haematol. 1999;107:69–79
  3. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin. Oncol. 1997;24:17–31
  4. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12. Blood. 2001;98:1752–1759
  5. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61:7233–7239
  6. Thiede C, Steudel C, Mohr B, et al. Analysis of Flt3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–4335
  7. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637–2644
  8. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717–3721
  9. Aguayo A, Kantarjian HM, Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002;95:1923–1930
  10. Lai R, Estey E, Shen Y, et al. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer. 2002;94:14–17
  11. Torok-Storb B, Iwata M, Graf L, Gianotti J, Horton H, Byrne MC. Dissecting the marrow microenvironment. Ann NY Acad. Sci. 1999;872:164–170
  12. Rougier F, Dupuis F, Denizot Y. Human bone marrow fibroblasts—an overview of their characterization, proliferation and inflammatory mediator production. Hematol Cell Ther. 1996;38:241–246
  13. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology and potential applications. Stem Cells. 2001;19:180–192
  14. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol. 2001;29:448–457
  15. Bruserud Ø. Effects of dipyridamole, theophyllamine and verapamil on spontaneous proliferation of myelogenous leukemia cells. Acta Oncol. 1992;31:53–58
  16. Bruserud Ø, Gjertsen BT, Brustugun OT, et al. Effect of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia. 1995;9:1910–1920
  17. Bruserud Ø, Gjertsen BT, von Volkman HL. In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. J Hematother Stem Cell Res. 2000;9:923–932
  18. Bruserud Ø, Huang TS, Glenjen N, Gjertsen BT, Foss B. Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemic blasts. Haematologia. 2002;87:584–595
  19. Bruserud Ø, Glenjen NI, Ryningen A, Ulvestad E. In vitro culture of human acute myelogenous leukemia (ALL) cells in serum-free media: a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines. Leukemia Res. 2002;27:455–464
  20. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184:39–51
  21. Sitnicka E, Wang QR, Tsai S, Wolf NS. Support versus inhibition of hematopoiesis by two characterized stromal cell types.. Stem cells. 1995;13(6):655–665
  22. Lichtman MA. Interrupting the inhibition of normal hematopoiesis in myelogenous leukemia: a hypothetical approach to therapy. Stem Cells. 2000;18:304–306
  23. Bruserud Ø, Gjertsen BT, Foss B, Huang T-s. New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of AML cells—the present use in experimental studies and the possible importance for future therapeutic strategies. Stem Cells. 2001;19:1–11
  24. Motorin D, Bakken A, Foss Abrahamsen J, Ernst P, Bruserud O. Characterization of clonogenic progenitors in autologous peripheral blood stem cell grafts: evaluation of a simple in vitro assay suitable for routine clinical use. Hematology. 2003;8(5):313–318
  25. Bakken AM, Bruserud O, Abrahamsen JF. No differences in colony formation of peripheral blood stem cells frozen with 5 or 10% dimethyl sulfoxide. J Hematother Stem Cell Res. 2003;12(3):351–358
  26. Bruserud O, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica. 2004;89(4):391–402
  27. Bruserud O, Glenjen N, Gjertsen BT, Herfindal L, Doskeland SO. Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells. Expert Opin Biol Ther. 2002;2:197–210
  28. Glenjen N, Hovland R, Wergeland L, Wendelbo Ø, Ernst P, Bruserud Ø. The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status. Eur J Haematol. 2003;71:163–173
  29. Vinante F, Rigo A, Vincenzi C, Ricetti MM, Marrocchella R, Chilosi M, et al. IL-8 mRNA expression and IL-8 production by acute myeloid leukemia cells. Leukemia. 1993;7(10):1552–1556
  30. de Bont ES, Vellenga E, Molema G, van Wering E, de Leij LF, Kamps WA. A possible role for spontaneous interleukin-8 production by acute myeloid leukemic cells in angiogenesis related processes: work in progress. Med Pediatr Oncol. 2001;37(6):511–517
  31. Bruserud Ø, Hovland R, Wergeland L, Huang T-s, Gjertsen BT. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of the effects of Flt3-ligand in AML cell populations with and without Flt3 abnormalities. Haematologica. 2003;88:416–428

PII: S0145-2126(04)00233-4

doi: 10.1016/j.leukres.2004.06.008

Leukemia Research
Volume 29, Issue 2 , Pages 185-196 , February 2005

Article Tools

* Image Usage & Resolution